MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register
About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Deals review

Merck & Co., Inc. and Portola Enter Worldwide License Agreement to Develop and Commercialize Betrixaban, a Novel Investigational Oral Anticoagulant for Cardiovascular Disease

In order to access this content you must be logged in and have a subscription to PL Intelligence.

PLi

PL Intelligence is a one-stop environment for time-conscious executives. Keeping you abreast of the latest developments in the life sciences industry, saving you time and money when you need it most.

Subscribe now for instant access to the benefits PL Intelligence has to offer. Find out more.

Related deals

Portola Pharmaceuticals Enters Worldwide License Agreement for Development and Commercialization of Novel Antiplatelet Drug Elinogrel

BMS and Corgentech enter agreement to develop and commercialize cardiovascular therapy

Xenon Enters Cardiovascular Disease Collaboration with Merck & Co., Inc.

Bristol-Myers Squibb and Pfizer Announce Worldwide Collaboration to Develop and Commercialize Anticoagulant and Metabolic Compounds

Merck & Co., Inc. and Cardiome Sign License Agreement for Vernakalant, an Investigational Drug for Treatment of Atrial Fibrillation

Idera Pharmaceuticals and Merck & Co., Inc. Extend Research Collaboration for Agonists of Toll-like Receptors

Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins

Pfizer and Medivation Enter into Global Agreement to Co-Develop and Market Dimebon for the Treatment of Alzheimer's and Huntington's Diseases

Santhera and Biovail Enter into License Agreement to Develop and Commercialize JP-1730/Fipamezole in North America

Peptimmune is Granted Exclusive License from Genzyme to Develop and Commercialize Treatment for Metabolic Diseases including Obesity

Related categories

Therapeutic target
Central Nervous System

More deals

Latest deals

Strategic Collaboration with Kineta
Covalon and Amsino International advance joint activities
Dual-labeled probe manufacturing license agreement
Rosetta Genomics Names Genetic Technologies Limited Exclusive Distributor for Rosetta's microRNA-based Assays in Australia, New Zealand and Singapore
SKion GmbH makes a new, improved Tender Offer for Acquisition of ALTANA Shares

Most viewed deals

Bayer CropScience and Janssen PMP conclude research agreement:
Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded to Singapore and Vietnam
Bayer CropScience and Evogene to extend collaboration for rice yield improvement
Galapagos and Opsona Therapeutics initiate drug discovery collaboration
Merck & Co., Inc., Medarex, Inc. and Massachusetts Biologic Laboratories Sign Exclusive Licensing Agreement for Investigational Monoclonal Antibody Combination for Clostridium Difficile Infection

By month

November 2009
October 2009
September 2009
August 2009
July 2009
June 2009
May 2009
April 2009
March 2009
February 2009
January 2009
December 2008
November 2008

Clients in focus...

Get the Flash Player to see this rotator.

Partnering discussion free of charge
BioPartnering America
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us